Nothing Special   »   [go: up one dir, main page]

CY1124478T1 - Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret - Google Patents

Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret

Info

Publication number
CY1124478T1
CY1124478T1 CY20211100784T CY211100784T CY1124478T1 CY 1124478 T1 CY1124478 T1 CY 1124478T1 CY 20211100784 T CY20211100784 T CY 20211100784T CY 211100784 T CY211100784 T CY 211100784T CY 1124478 T1 CY1124478 T1 CY 1124478T1
Authority
CY
Cyprus
Prior art keywords
kinase inhibitors
ret kinase
heterocyclic compounds
ret
compounds
Prior art date
Application number
CY20211100784T
Other languages
English (en)
Inventor
Allan Jordan
Rebecca NEWTON
Bohdan Waszkowycz
Silvia PAOLETTA
Euan Alexander Fraser Fordyce
George Hynd
Jonathan Mark Sutton
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of CY1124478T1 publication Critical patent/CY1124478T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ενώσεις του Τύπου Ι που λειτουργούν ως αναστολείς της δραστικότητας ενζύμου κινάσης RET (αναδιατεταγμένη κατά τη διάρκεια επιμόλυνσης): όπου οι δεσμοί το ΗΕΤ, δεσμοί a, b, c και d, τα Χ1, X2, X3, Χ4, R2 και R3 είναι καθένα όπως ορίζεται στο παρόν. Η παρούσα εφεύρεση αφορά επίσης διεργασίες για την παρασκευή αυτών των ενώσεων σε φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτές και τη χρήση τους στη θεραπεία πολλαπλασιαστικών διαταραχών, όπως καρίνος, όπως επίσης άλλων νόσων ή καταστάσεων στις οποίες εμπλέκεται η δραστικότητα κινάσης RET.
CY20211100784T 2016-04-15 2021-09-06 Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret CY1124478T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201606631 2016-04-15
GB201619277 2016-11-14
PCT/GB2017/051076 WO2017178844A1 (en) 2016-04-15 2017-04-18 Heterocyclic compounds as ret kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1124478T1 true CY1124478T1 (el) 2022-07-22

Family

ID=58633035

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100784T CY1124478T1 (el) 2016-04-15 2021-09-06 Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret

Country Status (23)

Country Link
US (3) US10954241B2 (el)
EP (2) EP3960180A1 (el)
JP (3) JP6943876B2 (el)
KR (3) KR102706837B1 (el)
CN (2) CN109195972B (el)
AU (3) AU2017250448C1 (el)
BR (2) BR112018071097B1 (el)
CA (1) CA3020778A1 (el)
CY (1) CY1124478T1 (el)
DK (1) DK3442980T3 (el)
ES (1) ES2886587T3 (el)
HR (1) HRP20211362T1 (el)
HU (1) HUE056135T2 (el)
IL (3) IL297192A (el)
LT (1) LT3442980T (el)
MX (2) MX2018012609A (el)
PL (1) PL3442980T3 (el)
PT (1) PT3442980T (el)
RS (1) RS62322B1 (el)
RU (1) RU2742115C2 (el)
SG (2) SG10201911665UA (el)
SI (1) SI3442980T1 (el)
WO (1) WO2017178844A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY191934A (en) 2010-05-20 2022-07-19 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
JP6816100B2 (ja) 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物
MX2018005528A (es) 2015-11-02 2018-11-09 Blueprint Medicines Corp Inhibidores de ret.
HRP20221051T8 (hr) 2016-04-15 2023-07-21 Cancer Research Technology Limited Heterociklički spojevi kao inhibitori ret kinaze
RU2742115C2 (ru) 2016-04-15 2021-02-02 Кэнсер Рисерч Текнолоджи Лимитед Гетероциклические соединения в качестве ингибиторов киназы RET
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TW202410896A (zh) 2017-10-10 2024-03-16 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
TW201938169A (zh) * 2018-01-18 2019-10-01 美商亞雷生物製藥股份有限公司 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
WO2019192962A1 (en) * 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses hereof
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
BR112021006488A2 (pt) 2018-10-05 2021-07-06 Annapurna Bio Inc compostos e composições para o tratamento de condições associadas com atividade do receptor apj
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
WO2020200316A1 (zh) * 2019-04-03 2020-10-08 南京明德新药研发有限公司 作为ret抑制剂的吡唑并吡啶类化合物及其应用
CN115210226B (zh) * 2020-02-20 2024-01-09 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
CN113214294A (zh) * 2020-06-10 2021-08-06 深圳铂立健医药有限公司 三环化合物、药物组合物及其应用
MX2023003995A (es) 2020-10-05 2023-06-12 Enliven Inc Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.
TW202241419A (zh) * 2020-12-22 2022-11-01 美商基利科學股份有限公司 ６－取代之吲哚化合物
US20240059673A1 (en) * 2020-12-22 2024-02-22 Gilead Sciences, Inc. Substituted indole compounds
JP2024513945A (ja) 2021-04-16 2024-03-27 ギリアード サイエンシーズ， インコーポレイテッド チオノピロール化合物
CN113248518B (zh) * 2021-06-21 2022-03-25 山东大学 嘧啶哌嗪类衍生物及其制备方法与应用
CN117957234A (zh) 2021-09-10 2024-04-30 吉利德科学公司 噻吩并吡咯化合物
EP4415718A1 (en) 2021-10-15 2024-08-21 Stemline Therapeutics Inc. Inhibitors of mutant ret kinases for use in treating cancer
WO2024151519A2 (en) * 2023-01-09 2024-07-18 University Of Florida Research Foundatin, Incorporated Pparg modulators

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322779A3 (en) 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolactam compounds and pharmaceutical uses thereof
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
ES2206191T3 (es) * 1999-01-11 2004-05-16 Princeton University Inhibidores de alta afinidad para validacion de dianas y usos de los mismos.
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
MY148491A (en) * 2005-11-17 2013-04-30 Osi Pharm Inc FUSED BICYCLIC mTOR INHIBITORS
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007079164A2 (en) 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
GB0610242D0 (en) 2006-05-23 2006-07-05 Novartis Ag Organic compounds
JP2008063278A (ja) 2006-09-07 2008-03-21 Fujifilm Finechemicals Co Ltd １−ピリジン−４−イル−インドール類の製造方法
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
US20090274698A1 (en) * 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
CA2711558C (en) 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114870A2 (en) * 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
EP3009436B1 (en) * 2008-07-08 2019-06-05 Intellikine, LLC Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059593A1 (en) 2008-11-18 2010-05-27 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
EA036876B1 (ru) 2009-11-05 2020-12-30 Ризен Фармасьютикалз С.А. Ингибиторы pi3k киназы
US9765037B2 (en) 2010-01-28 2017-09-19 University Of Washington Through Its Center For Commercialization Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
WO2011094628A1 (en) 2010-01-28 2011-08-04 University Of Washington Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
US20130296316A1 (en) 2010-07-09 2013-11-07 Michael P. Pollastri Antiparasitic Agents Based On mTOR Inhibitors
US9295673B2 (en) * 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US20140357651A1 (en) 2011-05-04 2014-12-04 Yi Liu Combination pharmaceutical compositions and uses thereof
JP2014521725A (ja) 2011-08-10 2014-08-28 ノバルティス・ファルマ・アクチェンゲゼルシャフト ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法
CA2846496C (en) * 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
CN106994126A (zh) 2011-11-08 2017-08-01 因特利凯有限责任公司 使用多种药剂的治疗方案
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9738610B2 (en) 2012-09-24 2017-08-22 Whitehead Institute For Biomedical Research Indazole derivatives and uses thereof
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
US9724354B2 (en) 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use
WO2015069441A1 (en) 2013-10-18 2015-05-14 Medivation Technologies, Inc. Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
GB201321146D0 (en) * 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
JP6421241B2 (ja) 2014-11-14 2018-11-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ タンパク質キナーゼ阻害剤としての６−アミノ−７−ビシクロ−７−デアザ−プリン誘導体
WO2016123152A1 (en) 2015-01-26 2016-08-04 University Of Washington Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
EP4116303A1 (en) * 2015-09-16 2023-01-11 Loxo Oncology, Inc. Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
US20190077856A1 (en) 2016-03-15 2019-03-14 Memorial Sloan Kettering Cancer Center Method of treating diseases using kinase modulators
RU2742115C2 (ru) 2016-04-15 2021-02-02 Кэнсер Рисерч Текнолоджи Лимитед Гетероциклические соединения в качестве ингибиторов киназы RET
HRP20221051T8 (hr) * 2016-04-15 2023-07-21 Cancer Research Technology Limited Heterociklički spojevi kao inhibitori ret kinaze

Also Published As

Publication number Publication date
IL289793A (en) 2022-03-01
JP2021193108A (ja) 2021-12-23
NZ747678A (en) 2024-05-31
KR20220054894A (ko) 2022-05-03
US11548896B2 (en) 2023-01-10
PT3442980T (pt) 2021-09-13
JP2023159230A (ja) 2023-10-31
HUE056135T2 (hu) 2022-01-28
US20210155628A1 (en) 2021-05-27
US20190106425A1 (en) 2019-04-11
US10954241B2 (en) 2021-03-23
HRP20211362T1 (hr) 2021-11-26
JP6943876B2 (ja) 2021-10-06
AU2017250448C1 (en) 2021-01-07
AU2022203916A1 (en) 2022-06-23
US20230339954A1 (en) 2023-10-26
IL262185A (en) 2018-11-29
WO2017178844A1 (en) 2017-10-19
LT3442980T (lt) 2021-09-27
SG11201808878UA (en) 2018-11-29
KR20240142568A (ko) 2024-09-30
PL3442980T3 (pl) 2021-12-06
IL289793B (en) 2022-11-01
DK3442980T3 (da) 2021-08-30
EP3442980B1 (en) 2021-06-09
CN109195972A (zh) 2019-01-11
CN115650985A (zh) 2023-01-31
AU2020220079A1 (en) 2020-09-03
IL289793B2 (en) 2023-03-01
BR122023026297A2 (pt) 2024-01-16
CN115650985B (zh) 2024-08-02
CN109195972B (zh) 2022-10-28
JP2019515903A (ja) 2019-06-13
KR102390578B1 (ko) 2022-04-26
EP3442980A1 (en) 2019-02-20
AU2020220079B2 (en) 2022-04-21
MX2021013110A (es) 2021-11-17
SI3442980T1 (sl) 2021-11-30
RS62322B1 (sr) 2021-10-29
CA3020778A1 (en) 2017-10-19
SG10201911665UA (en) 2020-01-30
KR102706837B1 (ko) 2024-09-19
AU2017250448B2 (en) 2020-05-21
EP3960180A1 (en) 2022-03-02
BR112018071097B1 (pt) 2024-02-20
ES2886587T3 (es) 2021-12-20
IL297192A (en) 2022-12-01
BR112018071097A2 (pt) 2019-01-29
RU2018138471A (ru) 2020-05-15
MX2018012609A (es) 2019-08-01
AU2017250448A1 (en) 2018-11-01
IL262185B (en) 2022-02-01
KR20180134983A (ko) 2018-12-19
RU2742115C2 (ru) 2021-02-02
RU2018138471A3 (el) 2020-05-15

Similar Documents

Publication Publication Date Title
CY1124478T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις της κiνασης ret
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1123395T1 (el) Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1122550T1 (el) Αρυλικες, ετεροαρυλικες και ετεροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση των διαταραχων που διαμεσολαβουνται απο το συμπληρωμα
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1123025T1 (el) Αναστολεις βρωμοεπικρατειας
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
CY1126109T1 (el) Αναστολεις toy trpc6
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
BR112017009671A2 (pt) inibidores de ezh2 e usos destes
PH12018501248A1 (en) Biprazolyl derivatives useful for the treatment of autoimmune diseases
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
CY1120836T1 (el) Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина